Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CSPC Pharmaceutical Group Limited
  6. Summary
    1093   HK1093012172

CSPC PHARMACEUTICAL GROUP LIMITED

(1093)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
09/17/2021 09/20/2021 09/21/2021 09/23/2021 09/24/2021 Date
9.64 9.4 9.49 9.45 9.3 Last
36359910 21642000 30213830 51152330 42804220 Volume
+5.01% -2.49% +0.96% -0.42% -1.59% Change
Estimated financial data (e)
Sales 2021 33 936 M 4 359 M 4 359 M
Net income 2021 6 773 M 870 M 870 M
Net cash position 2021 11 473 M 1 474 M 1 474 M
P/E ratio 2021 16,5x
Yield 2021 1,80%
Sales 2022 39 675 M 5 096 M 5 096 M
Net income 2022 7 752 M 996 M 996 M
Net cash position 2022 15 854 M 2 036 M 2 036 M
P/E ratio 2022 14,4x
Yield 2022 1,94%
Capitalization 111 B 14 281 M 14 280 M
EV / Sales 2021 2,94x
EV / Sales 2022 2,40x
Nbr of Employees 23 300
Free-Float 70,6%
More Financials
Company
CSPC Pharmaceutical Group Ltd. specializes in the development, manufacture and marketing of pharmaceutical products. Net sames by category of products break down as follows: - drugs (78.7%): innovative drugs (62.5% of sales) and common generic drugs (37.5%); - vitamin C (10.1%); - antibiotics (6.2%); - other (5%): including anhydrous and raw caffeine. Net sales are distributed geographically as follows: China... 
Sector
Pharmaceuticals
Calendar
11/22Earnings Release
More about the company
Ratings of CSPC Pharmaceutical Group Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about CSPC PHARMACEUTICAL GROUP LIMITED
09/22KEYMED BIOSCIENCES : Partners With CSPC Pharmaceutical to Develop Potential Nervous System..
MT
09/16CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Year 2021, Payable ..
CI
09/10CSPC PHARMACEUTICAL GROUP LIMITED : Ex-dividend day for interim dividend
FA
09/03CSPC PHARMACEUTICAL : Secures Regulatory Nod for Phase 1 Clinical Trial of Cancer Treatmen..
MT
09/02CSPC PHARMACEUTICAL : Secures Registration Approval for Influenza Treatment in China
MT
09/01CSPC PHARMACEUTICAL : Voluntary announcement - "oseltamivir phosphate capsules" obtains dr..
PU
08/27HANG SENG : Hong Kong Hang Seng See-Saws Flat, as Tech Shares Slip
MT
08/27CSPC PHARMACEUTICAL : H1 Profit Rises 32% as Higher Drug Sales Boost Revenue
MT
08/26CSPC Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June..
CI
08/26CSPC Pharmaceutical Group Limited Declares an Interim Dividend for 2021, Payable on 8 O..
CI
08/23CSPC PHARMACEUTICAL : Arm Secures Licensing Deal for Breast, Gastric Cancer Treatments in ..
MT
08/16Hong Kong Hang Seng Down 0.8% on Renewed Tech Slump, Pandemic and China Outlook
MT
08/10CSPC PHARMACEUTICAL : Pharma's Cancer Drug Wins Registration Approval in China
MT
08/09CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval for Afatinib Dimal..
CI
07/23HANG SENG : Hong Kong Hang Seng Down 1.45% on Tech, Property Slump
MT
More news
News in other languages on CSPC PHARMACEUTICAL GROUP LIMITED
09/16CSPC Pharmaceutical Group Limited déclare un dividende intérimaire pour l'année 2021, p..
08/27Le Hang Seng de Hong Kong reste plat, les valeurs technologiques dégringolent
08/27Le bénéfice de CSPC Pharmaceutical au premier semestre augmente de 32 % grâce à la haus..
05/24STOCK MARKET PARIS : La recherche de catalyseurs haussiers patine
05/24EN DIRECT DES MARCHES : Airbus, EssilorLuxottica, Solutions 30, Tarkett, Boeing, Coca-Cola..
More news
Analyst Recommendations on CSPC PHARMACEUTICAL GROUP LIMITED
More recommendations
Chart CSPC PHARMACEUTICAL GROUP LIMITED
Duration : Period :
CSPC Pharmaceutical Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSPC PHARMACEUTICAL GROUP LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 28
Last Close Price 9,30 HKD
Average target price 13,84 HKD
Spread / Average Target 48,8%
EPS Revisions
Managers and Directors
Dong Chen Cai Chairman & Co-Chief Executive Officer
Cuilong Zhang Vice Chairman & Co-Chief Executive Officer
Bo Wang Independent Non-Executive Director
Chuan Chen Independent Non-Executive Director
Chun Kwok Au Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CSPC PHARMACEUTICAL GROUP LIMITED17.28%14 281
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037